Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Covington
Deloitte
Johnson and Johnson
Farmers Insurance
Novartis
UBS
Argus Health
AstraZeneca
Teva

Generated: August 22, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title:Aryl fused azapolycyclic compounds
Abstract: This invention is directed to compounds of the formula (I): ##STR00001## and their pharmaceutically acceptable salts, wherein R.sup.1, R.sup.2, and R.sup.3 are as defined herein; intermediates for the synthesis of such compounds, pharmaceutical compositions containing such compounds; and methods of using such compounds in the treatment of neurological and psychological disorders.
Inventor(s): Coe; Jotham Wadsworth (Niantic, CT), Brooks; Paige Roanne Palmer (North Stonington, CT)
Assignee: Pfizer Inc (New York, NY)
Filing Date:Jan 03, 2003
Application Number:10/336,532
Claims:1. A compound selected from the group consisting of: (-)-5,13-diazatetracyclo[9.3.1.0.sup.2,10.0.sup.4,8]pentadeca-2,4(8),9-tr- ien-6-one; (-)-6-oxo-5-oxa-7,13-diazatetracyclo[9.3.1.0.sup.2,10.0.sup.4,8- ]pentadeca-2(10),3,8-triene; (-)-2-fluoro-N-(4-hydroxy-10-aza-tricyclo[6.3.1.0.sup.2,7]dodeca-2(7),3,5- -trien-5-yl)-benzamide; (-)-7-dimethylamino-5-thia-5-dioxo-6,13-diazatetracyclo[9.3.1.0.sup.2,10.- 0.sup.4,8]pentadeca-2(10),3,6,8-tetraene; (-)-5-oxa-7-methyl-6-oxo-7,13-diazatetracyclo[9.3.1.0.sup.2,10.0.sup.4,8]- pentadeca-2(10),3,8-triene; (-)-6-methyl-5-thia-7,13-diazatetracyclo[9.3.1.0.sup.2,10.0.sup.4,8]penta- deca-2(10),3,6,8-tetraene; (-)-6-methyl-7-propyl-5,7,13-triazatetracyclo[9.3.1.0.sup.2,10.0.sup.4,8]- pentadeca-2(10),3,5,8-tetraene; (-)-6,7-dimethyl-5,7,13-triazatetracyclo[9.3.1.0.sup.2,10.0.sup.4,8]penta- deca-2(10),3,5,8-tetraene; (-)-7-propyl-5,7,13-triazatetracyclo[9.3.1.0.sup.2,10.0.sup.4,8]pentadeca- -2(10),3,5,8-tetraene; (-)-7-butyl-5,7,13-triazatetracyclo[9.3.1.0.sup.2,10.0.sup.4,8]pentadeca-- 2(10),3,5,8-tetraene; (-)-6-methyl-7-isobutyl-5,7,13-triazatetracyclo[9.3.1.0.sup.2,10.0.sup.4,- 8]pentadeca-2(10),3,5,8-tetraene; (-)-7-phenyl-5,7,13-triazatetracyclo[9.3.1.0.sup.2,10.0.sup.4,8]pentadeca- -2(10),3,5,8-tetraene; (-)-6-methyl-7-phenyl-5,7,13-triazatetracyclo[9.3.1.0.sup.2,10.0.sup.4,8]- pentadeca-2(10),3,5,8-tetraene; (-)-7-neopentyl-5,7,13-triazatetracyclo[9.3.10.sup.2,10.0.sup.4,8]pentade- ca-2(10),3,5,8-tetraene; (-)-6-methyl-7-neopentyl-5,7,13-triazatetracyclo[9.3.1.0.sup.2,10.0.sup.4- ,8]pentadeca-2(10),3,5,8-tetraene; (-)-5-oxa-7,13-diazatetracyclo[9.3.1.0.sup.2,10.0.sup.4,8]pentadeca-2(10)- ,3,6,8-tetraene; (-)-6-methyl-5-oxa-7,13-diazatetracyclo[9.3.1.0.sup.2,10.0.sup.4,8]pentad- eca-2(10),3,6,8-tetraene; and pharmaceutically acceptable salts thereof.

2. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.

3. A method for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal, comprising administering to said mammal an amount of a compound according to claim 1 that is effective in reducing nicotine addiction or aiding in the cessation or lessening of tobacco use.

4. A method for treating a disorder or condition selected from inflammatory bowel disease, ulcerative colitis, pyoderma gangrenosum, Crohn's disease, irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis, cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy; chemical dependencies and addictions; dependencies or, or addictions to, nicotine, tobacco products, alcohol, benzodiazepines, barbiturates, opioids or cocaine; headache, migraine, stroke, traumatic brain injury, obsessive-compulsive disorder, psychosis, Huntington's chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age-related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type, Parkinson's disease, attention deficit hyperactivity disorder and Tourette's Syndrome in a mammal, comprising administering to a mammal in need of such treatment an amount of a compound according to claim 1 that is effective in treating such disorder or condition.

5. A method for treating attention deficit hyperactivity disorder in a mammal, comprising administering to said mammal an amount of a compound according to claim 1 that is effective in attention deficit hyperactivity disorder.

6. A method for treating Tourette's Syndrome in a mammal, comprising administering to said mammal an amount of a compound according to claim 1 and pharmaceutically acceptable salts therof.

7. A compound selected from the group consisting of: (-)-4-methyl-10-aza-tricyclo[6.3.1.0.sup.2,7]dodeca-2(7),3,5-triene; (-)-4-nitro-10-azatricyclo[6.3.1.0.sup.2,7]dodeca-2(7),3,5-triene; (-)-4-amino-10-azatricyclo[6.3.1.0.sup.2,7]dodeca-2(7),3,5-triene; (-)-N.sup.1-[10-azatricyclo[6.3.1.0.sup.2,7]dodeca-2(7),3,5-trien-4-yl]ac- etamide; (-)-4-chloro-10-azatricyclo[6.3.1.0.sup.2,7]dodeca-2(7),3,5-trien- e; (-)-3-(10-azatricyclo[6.3.1.0.sup.2,7]dodeca-2(7),3,5-trien-4-yl)-5-met- hyl-1,2,4-oxadiazole; (-)-10-azatricyclo[6.3.1.0.sup.2,7]dodeca-2(7),3,5-trien-4-ol; (-)-N.sup.4,N.sup.4-dimethyl-10-azatricyclo[6.3.1.0.sup.2,7]dodeca-2(7),3- ,5-triene-4-sulfonamide; (-)-4-(1-pyrrolidinylsulfonyl)-10-azatricyclo[6.3.1.0.sup.2,7]dodeca-2(7)- ,3,5-triene; (-)-5-fluoro-10-aza-tricyclo[6.3.1.0.sup.2,7]dodeca-2(7),3,5-triene-4-car- bonitrile; (-)-4-ethynyl-5-fluoro-10-aza-tricyclo[6.3.1.0.sup.2,7]dodeca-2- (7),3,5-triene; (-)-5-ethynyl-10-aza-tricyclo[6.3.1.0.sup.2,7]dodeca-2(7),3,5-triene-4-ca- rbonitrile; (-)-5-chloro-10-aza-tricyclo[6.3.1.0.sup.2,7]dodeca-2(7),3,5-triene-4-car- bonitrile; (-)-4-ethynyl-5-chloro-10-aza-tricyclo[6.3.1.0.sup.2,7]dodeca-2- (7),3,5-triene; (-)-4-fluoro-5-trifluoromethyl-10-aza-tricyclo[6.3.1.0.sup.2,7]dodeca-2(7- ),3,5-triene; (-)-4-chloro-5-trifluoromethyl-10-aza-tricyclo[6.3.1.0.sup.2,7]dodeca-2(7- ),3,5-triene; (-)-5-trifluoromethyl-10-aza-tricyclo[6 .3.1.0.sup.2,7]dodeca-2(7),3,5-triene-4-carbonitrile; (-)-4-ethynyl-5-trifluoromethyl-10-aza-tricyclo[6.3.1.0.sup.2,7]dodeca-2(- 7),3,5-triene; and pharmaceutically acceptable salts thereof.

8. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to claim 7 and a pharmaceutically acceptable carrier.

9. A method for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal, comprising administering to said mammal an amount of a compound according to claim 7 that is effective in reducing nicotine addiction or aiding in the cessation or lessening of tobacco use.

10. A method for treating a disorder or condition selected from inflammatory bowel disease, ulcerative colitis, pyoderma gangrenosum, Crohn's disease, irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis, cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy; chemical dependencies and addictions; dependencies or, or addictions to, nicotine, tobacco products, alcohol, benzodiazepines, barbiturates, opioids or cocaine; headache, migraine, stroke, traumatic brain injury, obsessive-compulsive disorder, psychosis, Huntington's chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age-related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type, Parkinson's disease, attention deficit hyperactivity disorder and Tourette's Syndrome in a mammal, comprising administering to a mammal in need of such treatment an amount of a compound according to claim 7 that is effective in treating such disorder or condition.

11. A method for treating attention deficit hyperactivity disorder in a mammal, comprising administering to said mammal an amount of a compound according to claim 7 that is effective in attention deficit hyperactivity disorder.

12. A method for treating Tourette's Syndrome in a mammal, comprising administering to said mammal an amount of a compound according to claim 7 that is effective in treating Tourette's Syndrome.

13. A compound selected from the group consisting of: (-)-3-trifluoromethyl-10-aza-tricyclo[6.3.1.0.sup.2,7]dodeca-2(7),3,5-tri- ene; (-)-4-trifluoromethyl-10-aza-tricyclo[6.3.1.0.sup.2,7]dodeca-2(7),3,5- -triene; (-)-3-fluoro-10-aza-tricyclo[6.3.1.0.sup.2,7]dodeca-2(7),3,5-trie- ne; (-)-10-azatricyclo[6.3.1.0.sup.2,7]dodeca-2(7),3,5-trien-4-yl cyanide; (-)-4-fluoro-10-aza-tricyclo[6.3.1.0.sup.2,7]dodeca-2(7),3,5-triene; and pharmaceutically acceptable salts thereof.

14. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound to claim 13 and a pharmaceutically acceptable carrier.

15. A method for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal, comprising administering to said mammal an amount of a compound according to claim 13 that is effective in reducing nicotine addiction or aiding in the cessation or lessening of tobacco use.

16. A method for treating a disorder or condition selected from inflammatory bowel disease, ulcerative colitis, pyoderma gangrenosum, Crohn's disease, irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis, cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy; chemical dependencies and addictions; dependencies or, or addictions to, nicotine, tobacco products, alcohol, benzodiazepines, barbiturates, opioids or cocaine; headache, migraine, stroke, traumatic brain injury, obsessive-compulsive disorder, psychosis, Huntington's chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age-related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type, Parkinson's disease, attention deficit hyperactivity disorder and Tourette's Syndrome in a mammal, comprising administering to a mammal in need of such treatment an amount of a compound according to claim 13 that is effective in treating such disorder or condition.

17. A method for treating attention deficit hyperactivity disorder in a mammal, comprising administering to said mammal an amount of a compound according to claim 13 that is effective in attention deficit hyperactivity disorder.

18. A method for treating Tourette's Syndrome in a mammal, comprising administering to said mammal an amount of a compound according to claim 13 that is effective in treating Tourette's Syndrome.

19. A compound selected from the group consisting of: (-)-5,14-diazatetracyclo[10.3.1.0.sup.2,11.0.sup.4,9]hexadeca-2(11),3,5,7- ,9-pentaene; (-)-6-methyl-5,14-diazatetracyclo[10.3.1.0.sup.2,11.0.sup.4,9]hexadeca-2(- 11),3,5,7,9-pentaene; (-)-7-methyl-5,14-diazatetracyclo[10.3.1.0.sup.2,11.0.sup.4,9]hexadeca-2(- 11),3,5,7,9-pentaene; (-)-7-ethyl-5,14-diazatetracyclo[10.3.1.0.sup.2,11.0.sup.4,9]hexadeca-2(1- 1),3,5,7,9-pentaene; (-)-8-methyl-5,14-diazatetracyclo[10.3.1.0.sup.2,11.0.sup.4,9]hexadeca-2(- 11),3,5,7,9-pentaene; (-)-5,14-diazatetracyclo[10.3.1.0.sup.2,11.0.sup.4,9]hexadeca-2(11),3,7,9- -tetraen-6-one; (-)-6-chloro-5,14-diazatetracyclo[10.3.1.0.sup.2,11.0.sup.4,9]hexadeca-2(- 11),3,5,7,9-pentaene; (-)-6-methoxy-5,14-diazatetracyclo[10.3.1.0.sup.2,11.0.sup.4,9]hexadeca-2- (11),3,5,7,9-pentaene; (-)-6-chloro-10-fluoro-5,14-diazatetracyclo[10.3.1.0.sup.2,11.0.sup.4,9]h- exadeca-2(11),3,5,7,9-pentaene; (-)-6-chloro-3-fluoro-5,14-diazatetracyclo[10.3.1.0.sup.2,11.0.sup.4,9]he- xadeca-2(11),3,5,7,9-pentaene; and pharmaceutically acceptable salts thereof.

20. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to claim 19 and a pharmaceutically acceptable carrier.

21. A method for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal, comprising administering to said mammal an amount of a compound according to claim 19 that is effective in reducing nicotine addiction or aiding in the cessation or lessening of tobacco use.

22. A method for treating a disorder or condition selected from inflammatory bowel disease, ulcerative colitis, pyoderma gangrenosum, Crohn's disease, irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis, cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy; chemical dependencies and addictions; dependencies or, or addictions to, nicotine, tobacco products, alcohol, benzodiazepines, barbiturates, opioids or cocaine; headache, migraine, stroke, traumatic brain injury, obsessive-compulsive disorder, psychosis, Huntington's chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age-related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type, Parkinson's disease, attention deficit hyperactivity disorder and Tourette's Syndrome in a mammal, comprising administering to a mammal in need of such treatment an amount of a compound according to claim 19 that is effective in treating such disorder or condition.

23. A method for treating attention deficit hyperactivity disorder in a mammal, comprising administering to said mammal an amount of a compound according to claim 19 that is effective in attention deficit hyperactivity disorder.

24. A method for treating Tourette's Syndrome in a mammal, comprising administering to said mammal an amount of a compound according to claim 19 that is effective in treating Tourette's Syndrome.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
US Army
US Department of Justice
Mallinckrodt
Cantor Fitzgerald
QuintilesIMS
Daiichi Sankyo
Cipla
Federal Trade Commission
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot